Company Description
Anavex Life Sciences Corp. operates as a biopharmaceutical company.
It engages in developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer .
Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome.
Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors.
The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy.
The company’s ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies.
Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Terrie Kellmeyer |
Contact Details
Address: 630 5th Avenue, 20th Floor New York, New York 10111 United States | |
| Phone | 844 689 3939 |
| Website | anavex.com |
Stock Details
| Ticker Symbol | AVXL |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001314052 |
| CUSIP Number | 032797300 |
| ISIN Number | US0327973006 |
| Employer ID | 98-0608404 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Terrie Kellmeyer Ph.D. | Interim Chief Executive Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 18, 2026 | DFAN14A | Filing |
| Sep 17, 2026 | DFAN14A | Filing |
| Sep 15, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 15, 2026 | DFAN14A | Filing |
| Sep 14, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Sep 10, 2026 | DFAN14A | Filing |
| Sep 10, 2026 | DFAN14A | Filing |
| Sep 9, 2026 | DFAN14A | Filing |
| Sep 9, 2026 | 8-K | Current Report |
| Sep 8, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |